UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 8, 2017
Amyris, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-34885 | 55-0856151 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
5885 Hollis Street, Suite 100, Emeryville, CA | 94608 | ||
(Address of principal executive offices) | (Zip Code) |
(510) 450-0761 | ||
(Registrant’s telephone number, including area code) |
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.02 | Unregistered Sales of Equity Securities. |
The information contained in Item 8.01 below is incorporated herein by reference.
Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
The information contained in Item 8.01 below is incorporated herein by reference.
Item 8.01 | Other Events. |
As previously reported, on May 8, 2017, Amyris, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) for the issuance and sale of 22,140 shares of the Company’s Series A 17.38% Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), 65,203.8756 shares of the Company’s Series B 17.38% Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”), and Cash Warrants (as defined in the Prior 8-K (as defined below)) to purchase an aggregate of 207,954,414 shares of the Company’s common stock, par value $0.0001 per share, and Dilution Warrants (as defined in the Prior 8-K) (collectively, the “Warrants”) (the “Offering”). The entry into the Purchase Agreement and related matters were reported in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on May 8, 2017 (the “Prior 8-K”), which is incorporated herein by reference.
On May 8, 2017, the Company filed the Certificates of Designation of Preferences, Rights and Limitations relating to the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock (as defined in the Prior 8-K) with the Secretary of State of Delaware.
On May 11, 2017, the Company and the Investors closed the issuance and sale of the Series A Preferred Stock, Series B Preferred Stock and Warrants, resulting in net proceeds to the Company of approximately $44.5 million after payment of offering expenses and placement agent fees. In addition, on May 11, 2017, the Company consummated the Exchange (as defined in the Prior 8-K) and entered into the Stockholder Agreement (as defined in the Prior 8-K), License Agreements (as defined in the Prior 8-K) and a related intellectual property escrow agreement with DSM International B.V., a subsidiary of Koninklijke DSM N.V.
Rodman & Renshaw (“Rodman”), a unit of H.C. Wainwright & Co., LLC, acted as placement agent in connection with the Offering, subject to the terms and conditions of an engagement letter between the Company and Rodman, which was filed as Exhibit 10.2 to the Prior 8-K (the “Engagement Letter”). On May 9, 2017, the Company and Rodman entered into an amendment to the Engagement Letter to clarify the fees receivable by Rodman in connection with the Offering and provide certain rights to Rodman with respect to future financing transactions by the Company.
The Series A Preferred Stock was offered and sold pursuant to a prospectus filed with the SEC on April 9, 2015 and a prospectus supplement dated May 8, 2017 (collectively, the “Prospectus”), in connection with a takedown from the Company’s effective shelf registration statement on Form S-3 (File No. 333-203216) declared effective by the SEC on April 15, 2015. The legal opinion of the Company’s counsel, Fenwick & West LLP, regarding the validity of the Series A Preferred Stock offered pursuant to the Prospectus is filed herewith as Exhibit 5.01.
The Series B Preferred Stock and Warrants were issued in a private placement pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D promulgated under the Securities Act.
The Series C Preferred Stock was issued in a private exchange pursuant to the exemption from registration under Section 3(a)(9) of the Securities Act.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit Number |
Description |
5.01 | Opinion of Fenwick & West LLP |
23.01 | Consent of Fenwick & West LLP (included in Exhibit 5.01) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMYRIS, INC. | |||
Date: May 11, 2017 | By: | /s/ Kathleen Valiasek | |
Kathleen Valiasek | |||
Chief Financial Officer |
EXHIBIT INDEX
Exhibit Number |
Description |
5.01 | Opinion of Fenwick & West LLP |
23.01 | Consent of Fenwick & West LLP (included in Exhibit 5.01) |
EXHIBIT 5.01
May 11, 2017
Amyris, Inc.
5885 Hollis Street, Ste. 100
Emeryville, California 94608
Ladies and Gentlemen:
We deliver this opinion with respect to certain matters in connection with the offering by Amyris, Inc., a Delaware corporation (the “Company”), of an aggregate of 22,140 shares of the Company’s Series A 17.38% Convertible Preferred Stock, par value $0.0001 per share (the “Preferred Shares”) and shares (the “Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”), which are issuable upon conversion of the Preferred Shares pursuant to a Securities Purchase Agreement, dated May 8, 2017, between the Company and the Purchasers named therein (the “Purchase Agreement”). We have examined the Registration Statement on Form S-3 (File No. 333-203216) filed by the Company with the Securities and Exchange Commission (the “Commission”) on April 2, 2015, as subsequently amended on April 9, 2015, and declared effective on April 15, 2015 (the “Registration Statement”), under the Securities Act of 1933, as amended (the “Securities Act”), the prospectus contained within the Registration Statement (the “Base Prospectus”), and the related prospectus supplement dated May 8, 2017, filed with the Commission pursuant to Rule 424(b) under the Securities Act (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”).
As to matters of fact relevant to this opinion, we have examined such matters of fact as we have deemed necessary in order to render the opinion set forth herein, which included examination of the documents described on Exhibit A attached hereto (which is incorporated in this letter by reference). Capitalized terms used but not defined in the body of this letter have the meanings given to such terms on Exhibit A hereto.
In our examination of documents for purposes of this opinion, we have assumed, and express no opinion as to, the genuineness of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same, the lack of any undisclosed termination, modification, waiver or amendment to any document reviewed by us, the absence of any other extrinsic agreements or documents that might change or affect the interpretation or terms of any document we have reviewed and the due authorization, execution and delivery of all documents by all parties thereto. We have also assumed that any certificates or instruments representing the Shares have been, or will be when issued, properly signed by authorized officers of the Company or their agents.
We render this opinion only with respect to, and express no opinion herein concerning the application or effect of the laws of any jurisdiction other than the existing Delaware General Corporation Law (the “Applicable Laws”).
With respect to our opinion expressed in paragraph (1) below as to the valid existence and good standing of the Company under the laws of the State of Delaware, we have relied solely upon the Good Standing Certificate and representations made to us by the Company.
With respect to our opinion expressed in paragraph (3) below, we have assumed that (i) at or prior to the time of issuance of the Shares, the Registration Statement will not have been modified, withdrawn or deregistered and that there will not have occurred any change in law affecting the validity of the issuance of the Shares and (ii) the Preferred Shares will remain outstanding through the time of issuance of any Shares and will not be amended in any manner that effects the validity of the issuance of any Shares.
With respect to our opinions expressed in paragraph (3) below, we have also assumed that: (a) no change or changes to the number of authorized or outstanding shares of Common Stock, to the par value per share of the Common Stock, or to any of the Preferred Stock will occur that would cause the conversion price per share of Common Stock under any of the Preferred Stock to be less than the par value per share of the Common Stock on any date a share of Common Stock is issued pursuant to any conversion of a Preferred Stock, or (ii) cause the Company to have insufficient authorized, unissued and unreserved shares of Common Stock available to satisfy in full its obligations to issue all of the Shares upon conversion of any of the Preferred Shares; and (b) if necessary, all required action, resolutions and approvals of the Company’s Board of Directors and stockholders will be timely and validly taken and obtained so that, at each time a Preferred Share is converted to acquire Shares, the number of Shares issuable upon such conversion or payment of principal will not exceed the number of shares of Common Stock then authorized under the Company’s Certificate of Incorporation that are not then (A) issued or outstanding or (B) reserved for issuance with respect to any other then outstanding securities (or reserves of securities) of the Company.
Opinions. Based upon and subject to the foregoing, we are of the following opinion:
(1) | The Company is a corporation validly existing, in good standing, under the laws of the State of Delaware. |
(2) | The Preferred Shares will, when delivered in the manner and for the consideration stated in the Registration Statement and the Prospectus, be validly issued, fully paid and nonassessable. |
(3) | The Shares will, when issued and delivered upon conversion of the Preferred Shares in the manner stated in the Registration Statement and Prospectus, be validly issued, fully paid and nonassessable. |
2 |
We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us, if any, in the Registration Statement, the Prospectus constituting a part thereof and any amendments thereto.
[The remainder of this page has intentionally been left blank]
3 |
This opinion is intended solely for use in connection with issuance and sale of the Preferred Shares subject to the Registration Statement and is not to be relied upon for any other purpose. In providing this letter, we are opining only as to the specific legal issues expressly set forth above, and no opinion shall be inferred as to any other matter or matters. This opinion is rendered on, and speaks only as of, the date of this letter first written above, is based solely on our understanding of facts in existence as of such date and does not address any potential changes in facts, circumstances or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention, whether or not such occurrence would affect or modify any of the opinions expressed herein.
Very truly yours, | |||
FENWICK & WEST LLP | |||
By: | /s/ Daniel Winnike | ||
Daniel Winnike, a Partner |
4 |
EXHIBIT A
to
Legal Opinion Regarding S-3 Registration Statement
of Amyris, Inc., a Delaware corporation (the “Company”)
Certain Reviewed Documents
Capitalized terms used but not defined in this Exhibit A have the meanings defined for such terms in the Opinion Letter to which this Exhibit A is attached.
1. The Registration Statement and the Exhibits filed as a part thereof or incorporated therein by reference;
2. The Prospectus;
3. The Purchase Agreement;
4. The Company’s Restated Certificate of Incorporation, filed with the Delaware Secretary of State on September 30, 2010, and certified by the Delaware Secretary of State on September 30, 2010, as amended by that certain Certificate of Amendment of the Restated Certificate of Incorporation filed with the Delaware Secretary of State on May 9, 2013 and certified by the Delaware Secretary of State on May 9, 2013, that certain Certificate of Amendment of the above-described Restated Certificate of Incorporation, dated May 12, 2014 and certified by the Delaware Secretary of State on May 12, 2014, that certain Certificate of Amendment of the above-described Restated Certificate of Incorporation, dated September 18, 2015 and certified by the Delaware Secretary of State on September 18, 2015 and that certain Certificate of Amendment of the Restated Certificate of Incorporation, dated May 18, 2016 and certified by the Delaware Secretary of State on May 18, 2016 (such Restated Certificate of Incorporation of the Company, as so amended, the “Restated Certificate”);
5. A copy of the Certificate of Designation of Preferences, Rights and Limitations of Series A 17.38% Convertible Preferred Stock, filed with the Delaware Secretary of State on May 8, 2017;
6. The Company’s Restated Bylaws, certified by the Company’s Assistant Secretary on December 22, 2016 (the “Bylaws”);
7. Corporate proceedings and actions of the Company’s Board of Directors and stockholders with respect to the approval or authorization of the Restated Certificate and the Bylaws, the Purchase Agreement and the Registration Statement that have been provided to us by the Company;
8. Records of the outstanding capital stock and other outstanding securities of the Company that the Company has provided to us (including a certificate from the Company’s transfer agent of even date herewith verifying the number of the Company’s issued and outstanding shares of capital stock as of May 10, 2017);
9. A Certificate of Good Standing issued by the Delaware Secretary of State dated May 11, 2017, stating that the Company is duly incorporated under the laws of the State of Delaware and is in good standing under the laws of the State of Delaware (the “Good Standing Certificate”); and
5 |
10. Factual representations and warranties made to us by the Company, including those contained in an Opinion Certificate of the Company dated of even date herewith. We have assumed the current accuracy and completeness of the information obtained from the documents referred to above and the representations and warranties made by representatives of the Company to us. We have made no independent investigation or other attempt to verify the accuracy of any of such information or to determine the existence or non-existence of any other factual matters.
6